Literature DB >> 22300088

The inhibition of cell proliferation using silencing of N-cadherin gene by siRNA process in human melanoma cell lines.

D Ciołczyk-Wierzbicka1, D Gil, P Laidler.   

Abstract

Malignant melanoma is a disease with high mortality rate caused by rapid metastasis. Cell motility is physically and biochemically restricted by cadherin-mediated cell interactions and signalling pathways, and alterations in cadherin expression strongly correlate with E to N-cadherin switch as well as the metastasis and progression of tumours. Contrary to E-cadherin, N-cadherin plays an important role in stimulating processes of cell division, migration, differentiation and death. In this study we investigated the role of N-cadherin in proliferation and AKT, ERK, beta-catenin signalling pathway in human melanoma cells: WM793(VGP), WM115(VGP) from the primary tumor site, as well as Lu1205(lung) and WM266-4(skin) from metastatic sites. N-cadherin, pAKT(S473), β-catenin, pERK1/2(T202/Y204), cyclin D1, cyclin D3, cyclin-dependent kinases CDK4, CDK6, and p15, p16, p21, p27 inhibitors expression was determined by western blot analysis. The study on proliferation of cells was performed with the use of BrdU incorporation and crystal violet staining assays. Knock-out of N-cadherin gene expression by siRNA process reduced the expression of: pAKT(S473), pERK1/2(T202/Y204), betacatenin, cyclin D1, cyclin D3, cyclin-dependent kinases CDK4, CDK6 while increasing expression of cell cycle inhibitors p21 and p27, and significantly decreased cell proliferation (50-70%). The collected data indicate that N-cadherin mediates the effect of cell cycle in G1 phase by AKT, β-catenin, and ERK signalling pathway. These results suggest that increased expression of N-cadherin significantly contributes to the increased invasive potential of melanoma cells. Silencing of N-cadherin arrests cell growth at G1 phase and inhibits the entry into S-phase which is of great importance as to its possible future use in cancer treatment.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22300088     DOI: 10.2174/092986712803414006

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  14 in total

1.  Tissue inhibitor of metalloproteinase 2 inhibits activation of the β-catenin signaling in melanoma cells.

Authors:  Yuxuan Xia; Shaoping Wu
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

Review 2.  Molecular pathology of cutaneous melanoma.

Authors:  Léon C van Kempen; Margaret Redpath; Caroline Robert; Alan Spatz
Journal:  Melanoma Manag       Date:  2014-12-04

3.  E-cadherin-transfected neural stem cells transplantation for spinal cord injury in rats.

Authors:  Chen Zhang; Feng Tu; Ji-Yin Zhang; Lin Shen
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2014-08-19

4.  The biological effect and mechanism of the Wnt/β-catenin signaling pathway on malignant melanoma A375 cells.

Authors:  Yuxia Lin; Fangfei Wang; Qingfei Xing; Feng Guo; Mengzhen Wang; Yunjie Li
Journal:  Exp Ther Med       Date:  2018-07-06       Impact factor: 2.447

5.  MALT1 promotes melanoma progression through JNK/c-Jun signaling.

Authors:  Y Wang; G Zhang; J Jin; S Degan; Y Tameze; J Y Zhang
Journal:  Oncogenesis       Date:  2017-07-31       Impact factor: 7.485

6.  Protein kinase C inhibitor Gö6976 but not Gö6983 induces the reversion of E- to N-cadherin switch and metastatic phenotype in melanoma: identification of the role of protein kinase D1.

Authors:  Messaouda Merzoug-Larabi; Caroline Spasojevic; Marianne Eymard; Caroline Hugonin; Christian Auclair; Manale Karam
Journal:  BMC Cancer       Date:  2017-01-05       Impact factor: 4.430

7.  N-cadherin expression is associated with acquisition of EMT phenotype and with enhanced invasion in erlotinib-resistant lung cancer cell lines.

Authors:  Xiaoju Zhang; Guangzhi Liu; Yi Kang; Zhaogang Dong; Qiyu Qian; Xitao Ma
Journal:  PLoS One       Date:  2013-03-08       Impact factor: 3.240

8.  Gene therapy for advanced melanoma: selective targeting and therapeutic nucleic acids.

Authors:  Joana R Viola; Diana F Rafael; Ernst Wagner; Robert Besch; Manfred Ogris
Journal:  J Drug Deliv       Date:  2013-03-25

9.  Bidirectional functions of arsenic as a carcinogen and an anti-cancer agent in human squamous cell carcinoma.

Authors:  Nguyen Dinh Thang; Ichiro Yajima; Mayuko Y Kumasaka; Masashi Kato
Journal:  PLoS One       Date:  2014-05-09       Impact factor: 3.240

10.  Treatment of melanoma with selected inhibitors of signaling kinases effectively reduces proliferation and induces expression of cell cycle inhibitors.

Authors:  Dorota Ciołczyk-Wierzbicka; Dorota Gil; Piotr Laidler
Journal:  Med Oncol       Date:  2017-12-06       Impact factor: 3.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.